Manuel Alva, MD
Gastroenterology · Berwyn, ILNPI 1255405452
Payments from drug & device makers
Across 91 payments — averaging $22.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$474
- Johnson & Johnson$417
- AbbVie$257
- Boston Scientific$191
- Pfizer$143
- Gilead$136
- plus $389 from 9 others
What the payments were for
- Food & beverage$2,006100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $474 |
| Johnson & Johnson | 18 | $417 |
| AbbVie | 12 | $257 |
| Boston Scientific | 10 | $191 |
| Pfizer | 7 | $143 |
| Gilead | 4 | $136 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $74 |
| Ardelyx, Inc. | 2 | $65 |
| Intercept Pharmaceuticals, Inc. | 3 | $60 |
| Bristol Myers Squibb | 3 | $53 |
| Abiomed | 1 | $42 |
| Merck | 2 | $38 |
| Mauna Kea Technologies, Inc. | 1 | $26 |
| QOL Medical, LLC | 1 | $16 |
| Echosens North America, Inc. | 1 | $15 |
How this compares
$2,006 in reported general payments places this provider in the 55th percentile of 787 gastroenterology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 12 | $15,249 |
| Mesalamine ErMesalamine | 37 | $8,952 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 506 | $8,649 |
| Ursodiol | 22 | $3,509 |
| Rifabutin | 11 | $2,689 |
| Balsalazide Disodium | 12 | $1,851 |
| Cholestyramine LightCholestyramine | 15 | $1,524 |
| Famotidine | 92 | $972 |
| Pantoprazole Sodium | 103 | $687 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 19 | $377 |
| Sucralfate | 19 | $314 |
| Metronidazole | 34 | $298 |
| Amoxicillin | 36 | $241 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 11 | $216 |
| Rabeprazole Sodium | 11 | $153 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Berwyn
- Kamran AyubOak Lawn$4.3M
- David RubinChicago$3.6M
- Jonathan RosenbergGurnee$3.1M
- Stephen HanauerChicago$2.9M
- Parambir DulaiChicago$2.2M
- Charles BerkelhammerOak Lawn$1.9M
- Ikuo HiranoChicago$1.8M
- Manish BhuvaLake Barrington$1.7M
- Steven FlammChicago$1.6M
- Amar NaikDes Plaines$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.